Infectious Diseases in Obstetrics and Gynecology / 2011 / Article / Tab 1

Clinical Study

Chlamydia trachomatis and Mycoplasma genitalium Plasma Antibodies in Relation to Epithelial Ovarian Tumors

Table 1

Clinical characteristics for the women (291) with benign conditions, borderline ovarian tumors, epithelial ovarian cancer, or other pelvic malignancies included in the plasma antibody analyses.

Clinical characteristicsBenign conditions ( )BOT ( )EOC ( )Other pelvic malignancies ( )BOT versus benign, P valueEOC versus benign, P value

Age, y52 (18–87)53 (40–82)61 (31–78)58 (40–73)1.0b.003b
Menarchea, y13 (10–16), 13 (11–14), 13 (11–17), 13 (11–16), .9b.06b
Menopausea, y50 (40–57), 50 (44–54), 50 (43–61), 50 (41–55), 1.0b.2b
Paritya 2 (0–8), 2 (0–4), 2 (0–5), 3 (0–3), .6b.8b
 0 childrena37 (20%), 1 (7%), 12 (22%) 1 (9%), .5c.7d
 ≥3 childrena49 (26%), 3 (21%), 14 (26%) 6 (54%), 1.0c.9d
Oral contraceptive pill use ≥1 yeara61 (73%), 4 (80%), 17 (37%), 1 (12%), 1.0c<.001d
Past or current HRT usea37 (24%), 3 (27%), 14 (27%), 2 (18%), .7c.2d
Past or current smokinga54 (30%), 6 (50%), 18 (33%), 4 (36%), .2c.6d
History of PIDa12 (34%), 1 (14%), 4 (9%), 0 (0%), .4c.007d
BMIa26 (19–41), 24 (21–28), 25 (17–34), 26 (19–30), .4b.5b
Prospective plasma sample >1 year prior to diagnosis22 (11%) 011 (20%) 1 (8%)
Histology
 Serous SSPC,
 Mucinous
 Endometrioid Tubal cancer,
Uterine cancer,
Abdominal cancer,
Follicle cyst, Brenner tumor, Theca cell tumor, Fibroma,
Corpus luteum cyst,
Extra uterine pregnancy,
Tubo-ovarian abcess/sacto salpinx, Endometriosis, Gastrointestinal inflammation,
Other,
Normal,
Mixed EOC,
Undifferentiated EOC,
Clear cell tumor,
Undifferentiated tubal cancer,
Undifferentiated abdominal cancer,
Type 1 pathogenetic pathway19 (35%) 3 (25%)
Type 2 pathogenetic pathway35 (65%) 9 (75%)

Values are presented as medians and range (minimum and maximum values of age, menarche, menopause, parity, and BMI); or number and percentage of patients in each group (0 children, ≥3 children, oral contraceptive pill use ≥1 year, past or current HRT use, past or current smoking, history of PID: prospective plasma samples>1 year prior to diagnosis, type I pathogenetic pathway, and type II pathogenetic pathway).
BOT: borderline ovarian tumor; EOC: epithelial ovarian cancer; HRT: hormone replacement therapy; PID: pelvic inflammatory disease; BMI: body mass index; SSPC: Serous Surface Papillary Carcinoma.
aVariable with partial missing data.
bMann-Whitney U test.
cFisher’s exact test.
dChi-Square test.